October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
October 03, 2019
September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...
September 30, 2019
September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...
September 30, 2019
September 25, 2019 — Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting ...
September 25, 2019
September 5, 2019 — Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target ...
September 05, 2019
Feature | Peripheral Artery Disease (PAD) | Jeff Zagoudis, Associate Editor
August 28, 2019 — The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the ...
August 28, 2019
August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the ...
August 21, 2019
April 3, 2019 — Medtronic's Resolute Integrity Zotarolimus-eluting Coronary Stent System received an additional U.S ...
April 03, 2019
February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent ...
February 22, 2019
Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based ...
February 20, 2019
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat peripheral ...
January 30, 2019
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years ago ...
January 29, 2019
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003 ...
January 25, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few years ...
January 22, 2019
January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers ...
January 17, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now